{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:28Z","timestamp":1786982668674,"version":"build-2736575974"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s13555-024-01103-5","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:02:12Z","timestamp":1708041732000},"page":"341-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical and Disease Burden of Patients with Generalized Pustular Psoriasis: A Review of Real-World Evidence"],"prefix":"10.1007","volume":"14","author":[{"given":"Tina","family":"Bhutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Farberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"1103_CR1","first-page":"37","volume":"9","author":"K Ly","year":"2019","unstructured":"Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37\u201342.","journal-title":"Psoriasis (Auckl)"},{"key":"1103_CR2","first-page":"131","volume":"6","author":"KE Benjegerdes","year":"2016","unstructured":"Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131\u201344.","journal-title":"Psoriasis (Auckl)"},{"issue":"2","key":"1103_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/jdv.18720","volume":"37","author":"JC Prinz","year":"2023","unstructured":"Prinz JC, Choon SE, Griffiths CEM, Merola JF, Morita A, Ashcroft DM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review. J Eur Acad Dermatol Venereol. 2023;37(2):256\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 1","key":"1103_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40257-021-00654-z","volume":"23","author":"SE Choon","year":"2022","unstructured":"Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):21\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"1103_CR5","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"AA Navarini","year":"2017","unstructured":"Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Koks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1103_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","volume":"89","author":"A Onoufriadis","year":"2011","unstructured":"Onoufriadis A, Simpson MA, Pink AE, Di Meglio P, Smith CH, Pullabhatla V, et al. Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432\u20137.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"1103_CR7","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/jid.2012.490","volume":"133","author":"N Setta-Kaffetzi","year":"2013","unstructured":"Setta-Kaffetzi N, Navarini AA, Patel VM, Pullabhatla V, Pink AE, Choon SE, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133(5):1366\u20139.","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"1103_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00655-y","volume":"23","author":"S Marrakchi","year":"2022","unstructured":"Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1103_CR9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/1744666X.2022.2116003","volume":"18","author":"H Bachelez","year":"2022","unstructured":"Bachelez H, Barker J, Burden AD, Navarini AA, Krueger JG. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022;18(10):1033\u201347.","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"1103_CR10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1013068","volume":"365","author":"S Marrakchi","year":"2011","unstructured":"Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"1103_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1): e006450.","journal-title":"BMJ Open"},{"issue":"6","key":"1103_CR12","first-page":"669","volume":"16","author":"F Augey","year":"2006","unstructured":"Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16(6):669\u201373.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"1103_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2340\/00015555766871","volume":"76","author":"A Ohkawara","year":"1996","unstructured":"Ohkawara A, Yasuda H, Kobayashi H, Inaba Y, Ogawa H, Hashimoto I, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996;76(1):68\u201371.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1103_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5021\/ad.2017.29.6.761","volume":"29","author":"JY Lee","year":"2017","unstructured":"Lee JY, Kang S, Park JS, Jo SJ. Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean National Health Insurance Database. Ann Dermatol. 2017;29(6):761\u20137.","journal-title":"Ann Dermatol"},{"key":"1103_CR15","doi-asserted-by":"publisher","DOI":"10.5070\/D3247040909","author":"D Yan","year":"2018","unstructured":"Yan D, Afifi L, Jeon C, Cordoro KM, Liao W. A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol Online J. 2018. https:\/\/doi.org\/10.5070\/D3247040909.","journal-title":"Dermatol Online J"},{"issue":"1","key":"1103_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","volume":"140","author":"A Johnston","year":"2017","unstructured":"Johnston A, Xing X, Wolterink L, Barnes DH, Yin Z, Reingold L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109\u201320.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1103_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","volume":"143","author":"S Twelves","year":"2019","unstructured":"Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1103_CR18","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/jid.2013.230","volume":"133","author":"K Sugiura","year":"2013","unstructured":"Sugiura K, Takemoto A, Yamaguchi M, Takahashi H, Shoda Y, Mitsuma T, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133(11):2514\u201321.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1103_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","volume":"135","author":"S Hussain","year":"2015","unstructured":"Hussain S, Berki DM, Choon SE, Burden AD, Allen MH, Arostegui JI, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135(4):1067-70e9.","journal-title":"J Allergy Clin Immunol"},{"issue":"45","key":"1103_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023068","volume":"99","author":"ZJ Liu","year":"2020","unstructured":"Liu ZJ, Tian YT, Shi BY, Zhou Y, Jia XS. Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2020;99(45): e23068.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1103_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41423-020-0519-3","volume":"18","author":"R Uppala","year":"2021","unstructured":"Uppala R, Tsoi LC, Harms PW, Wang B, Billi AC, Maverakis E, et al. \u201cAutoinflammatory psoriasis\u201d-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307\u201317.","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"1103_CR22","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/ced.15227","volume":"47","author":"JP Chao","year":"2022","unstructured":"Chao JP, Tsai TF. Elderly-onset generalized pustular psoriasis: a case series. Clin Exp Dermatol. 2022;47(8):1567\u201370.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1103_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","volume":"53","author":"SE Choon","year":"2014","unstructured":"Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676\u201384.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1103_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/24755303211021786","volume":"6","author":"J Crowley","year":"2021","unstructured":"Crowley J, Golembesky AK, Kotowsky N, Gao R, Bohn RL, Garry EM, et al. Clinical characteristics and healthcare resource utilization in patients with generalized pustular psoriasis: real-world evidence from a large claims-based dataset. J Psoriasis Psoriatic Arthritis. 2021;6(3):151\u20138.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"1103_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jdin.2021.12.001","volume":"6","author":"GV Duarte","year":"2022","unstructured":"Duarte GV, de Esteves Carvalho AV, Romiti R, Gaspar A, de Gomes Melo T, Soares CP, et al. Generalized pustular psoriasis in Brazil: A public claims database study. JAAD Int. 2022;6:61\u20137.","journal-title":"JAAD Int"},{"key":"1103_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081171","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Girolomoni G. Clinical characteristics of patients with pustular psoriasis: a single-center retrospective observational study. Vaccines (Basel). 2022. https:\/\/doi.org\/10.3390\/vaccines10081171.","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"1103_CR27","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1080\/03007995.2021.1951192","volume":"37","author":"ML Hanna","year":"2021","unstructured":"Hanna ML, Singer D, Bender SD, Valdecantos WC, Wu JJ. Characteristics of hospitalizations and emergency department visits due to generalized pustular psoriasis in the United States. Curr Med Res Opin. 2021;37(10):1697\u2013703.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1103_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/03007995.2021.1894108","volume":"37","author":"ML Hanna","year":"2021","unstructured":"Hanna ML, Singer D, Valdecantos WC. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States. Curr Med Res Opin. 2021;37(5):735\u201342.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1103_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/1346-8138.15657","volume":"48","author":"K Hayama","year":"2021","unstructured":"Hayama K, Fujita H, Iwatsuki K, Terui T. Improved quality of life of patients with generalized pustular psoriasis in Japan: a cross-sectional survey. J Dermatol. 2021;48(2):203\u20136.","journal-title":"J Dermatol"},{"issue":"7","key":"1103_CR30","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/1346-8138.12863","volume":"42","author":"H Jin","year":"2015","unstructured":"Jin H, Cho HH, Kim WJ, Mun JH, Song M, Kim HS, et al. Clinical features and course of generalized pustular psoriasis in Korea. J Dermatol. 2015;42(7):674\u20138.","journal-title":"J Dermatol"},{"issue":"8","key":"1103_CR31","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/jdv.18103","volume":"36","author":"A Kara Polat","year":"2022","unstructured":"Kara Polat A, Alpsoy E, Kalkan G, Aytekin S, Ucmak D, Yasak Guner R, et al. Sociodemographic, clinical, laboratory, treatment and prognostic characteristics of 156 generalized pustular psoriasis patients in Turkey: a multicentre case series. J Eur Acad Dermatol Venereol. 2022;36(8):1256\u201365.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1103_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/1744666X.2019.1708193","volume":"16","author":"S Kharawala","year":"2020","unstructured":"Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"1103_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/ijd.13489","volume":"56","author":"BW Lau","year":"2017","unstructured":"Lau BW, Lim DZ, Capon F, Barker JN, Choon SE. Juvenile generalized pustular psoriasis is a chronic recalcitrant disease: an analysis of 27 patients seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2017;56(4):392\u20139.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1103_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/24755303221079814","volume":"7","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Medeiros RA, Mackey RH, Harrold LR, Valdecantos WC, Flack M, et al. The disease burden of generalized pustular psoriasis: real-world evidence from CorEvitas\u2019 psoriasis registry. J Psoriasis Psoriatic Arthritis. 2022;7(2):71\u20138.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"1103_CR35","first-page":"89","volume":"12","author":"S Lofvendahl","year":"2022","unstructured":"Lofvendahl S, Norlin JM, Schmitt-Egenolf M. Economic burden of generalized pustular psoriasis in Sweden: a population-based register study. Psoriasis (Auckl). 2022;12:89\u201398.","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"1103_CR36","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/bjd.20966","volume":"186","author":"S Lofvendahl","year":"2022","unstructured":"Lofvendahl S, Norlin JM, Schmitt-Egenolf M. Prevalence and incidence of generalized pustular psoriasis in Sweden: a population-based register study. Br J Dermatol. 2022;186(6):970\u20136.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1103_CR37","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/1744666X.2022.2118716","volume":"18","author":"J Lu","year":"2022","unstructured":"Lu J, Shi Y. A review of disease burden and clinical management for generalized pustular psoriasis in China. Expert Rev Clin Immunol. 2022;18(10):1023\u201332.","journal-title":"Expert Rev Clin Immunol"},{"key":"1103_CR38","doi-asserted-by":"publisher","first-page":"adv00685","DOI":"10.2340\/actadv.v102.2226","volume":"102","author":"Y Manone-Zenke","year":"2022","unstructured":"Manone-Zenke Y, Ohara Y, Fukui S, Kobayashi D, Sugiura K, Ikeda S, et al. Characteristics of patients with generalized pustular psoriasis and psoriatic arthritis: a retrospective cohort study. Acta Derm Venereol. 2022;102:adv00685.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1103_CR39","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaad.2021.06.008","volume":"86","author":"H Miyachi","year":"2022","unstructured":"Miyachi H, Konishi T, Kumazawa R, Matsui H, Shimizu S, Fushimi K, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1103_CR40","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/1346-8138.16022","volume":"48","author":"A Morita","year":"2021","unstructured":"Morita A, Kotowsky N, Gao R, Shimizu R, Okubo Y. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the Medical Data Vision claims database. J Dermatol. 2021;48(10):1463\u201373.","journal-title":"J Dermatol"},{"issue":"1","key":"1103_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/jamadermatol.2021.4640","volume":"158","author":"MH Noe","year":"2022","unstructured":"Noe MH, Wan MT, Mostaghimi A, Gelfand JM, Agnihothri R, Pustular Psoriasis in the USRG, et al. Evaluation of a case series of patients with generalized pustular psoriasis in the United States. JAMA Dermatol. 2022;158(1):73\u20138.","journal-title":"JAMA Dermatol."},{"issue":"1","key":"1103_CR42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/1346-8138.16217","volume":"49","author":"C Ohata","year":"2022","unstructured":"Ohata C, Tsuruta N, Yonekura K, Higashi Y, Saito K, Katayama E, et al. Clinical characteristics of Japanese pustular psoriasis: a multicenter observational study. J Dermatol. 2022;49(1):142\u201350.","journal-title":"J Dermatol"},{"issue":"7","key":"1103_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/1346-8138.16383","volume":"49","author":"J Ohn","year":"2022","unstructured":"Ohn J, Choi YG, Yun J, Jo SJ. Identifying patients with deteriorating generalized pustular psoriasis: development of a prediction model. J Dermatol. 2022;49(7):675\u201381.","journal-title":"J Dermatol"},{"issue":"11","key":"1103_CR44","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1111\/1346-8138.16084","volume":"48","author":"Y Okubo","year":"2021","unstructured":"Okubo Y, Kotowsky N, Gao R, Saito K, Morita A. Clinical characteristics and health-care resource utilization in patients with generalized pustular psoriasis using real-world evidence from the Japanese Medical Data Center database. J Dermatol. 2021;48(11):1675\u201387.","journal-title":"J Dermatol"},{"issue":"Suppl 1","key":"1103_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40257-021-00663-y","volume":"23","author":"DV Reisner","year":"2022","unstructured":"Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23(Suppl 1):65\u201371.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1103_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/24755303211021779","volume":"6","author":"JM Sobell","year":"2021","unstructured":"Sobell JM, Gao R, Golembesky AK, Kotowsky N, Garry EM, Comerford EO, et al. Healthcare resource utilization and baseline characteristics of patients with generalized pustular psoriasis: real-world results from a large US database of multiple commercial medical insurers. J Psoriasis Psoriatic Arthritis. 2021;6(3):143\u201350.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"2","key":"1103_CR47","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s13555-021-00493-0","volume":"11","author":"B Strober","year":"2021","unstructured":"Strober B, Kotowsky N, Medeiros R, Mackey RH, Harrold LR, Valdecantos WC, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529\u201341.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"1103_CR48","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1111\/1346-8138.16164","volume":"48","author":"T Tosukhowong","year":"2021","unstructured":"Tosukhowong T, Kiratikanon S, Wonglamsam P, Netiviwat J, Innu T, Rujiwetpongstorn R, et al. Epidemiology and clinical features of pustular psoriasis: a 15-year retrospective cohort. J Dermatol. 2021;48(12):1931\u20135.","journal-title":"J Dermatol"},{"issue":"3","key":"1103_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1590\/abd1806-4841.20175536","volume":"92","author":"Q Wang","year":"2017","unstructured":"Wang Q, Liu W, Zhang L. Clinical features of von Zumbusch type of generalized pustular psoriasis in children: a retrospective study of 26 patients in southwestern China. An Bras Dermatol. 2017;92(3):319\u201322.","journal-title":"An Bras Dermatol"},{"issue":"3","key":"1103_CR50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jdermsci.2016.11.008","volume":"85","author":"Y Wang","year":"2017","unstructured":"Wang Y, Cheng R, Lu Z, Guo Y, Yan M, Liang J, et al. Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes. J Dermatol Sci. 2017;85(3):235\u201340.","journal-title":"J Dermatol Sci"},{"issue":"10","key":"1103_CR51","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamadermatol.2022.3142","volume":"158","author":"CL Zema","year":"2022","unstructured":"Zema CL, Valdecantos WC, Weiss J, Krebs B, Menter AM. Understanding flares in patients with generalized pustular psoriasis documented in US electronic health records. JAMA Dermatol. 2022;158(10):1142\u20138.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1103_CR52","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1365-2133.2005.07071.x","volume":"154","author":"F Sampogna","year":"2006","unstructured":"Sampogna F, Tabolli S, Soderfeldt B, Axtelius B, Aparo U, Abeni D, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006;154(5):844\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1103_CR53","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaad.2023.04.066","volume":"89","author":"O Ericson","year":"2023","unstructured":"Ericson O, Lofvendahl S, Norlin JM, Gyllensvard H, Schmitt-Egenolf M. Mortality in generalized pustular psoriasis: a population-based national register study. J Am Acad Dermatol. 2023;89(3):616\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1103_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040740","author":"F Bellinato","year":"2023","unstructured":"Bellinato F, Gisondi P, Marzano AV, Piaserico S, De Simone C, Damiani G, et al. Characteristics of patients experiencing a flare of generalized pustular psoriasis: a multicenter observational study. Vaccines (Basel). 2023. https:\/\/doi.org\/10.3390\/vaccines11040740.","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"1103_CR55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ad.2022.09.012","volume":"114","author":"T Montero-Vilchez","year":"2023","unstructured":"Montero-Vilchez T, Grau-Perez M, Garcia-Doval I. Epidemiology and geographic distribution of generalized pustular psoriasis in Spain: a national population-based study of hospital admissions from 2016 to 2020. Actas Dermosifiliogr. 2023;114(2):97\u2013101.","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"1103_CR56","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00403-022-02429-w","volume":"315","author":"C Chaiyabutr","year":"2023","unstructured":"Chaiyabutr C, Silpa-Archa N, Wongpraprarut C, Likittanasombat S, Phumariyapong P, Chularojanamontri L. An analysis of psoriasis hospitalisation in Thailand. Arch Dermatol Res. 2023;315(4):779\u201386.","journal-title":"Arch Dermatol Res"},{"key":"1103_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19530","author":"SE Choon","year":"2023","unstructured":"Choon SE, De La Cruz C, Wolf P, Jha RK, Fischer KI, Goncalves-Bradley DC, et al. Health-related quality of life in patients with generalized pustular psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19530.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1103_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16949","author":"K Hayama","year":"2023","unstructured":"Hayama K, Iwasaki R, Tian Y, Fujita H. Factors associated with generalized pustular psoriasis progression among patients with psoriasis vulgaris in Japan: results from a claims database study. J Dermatol. 2023. https:\/\/doi.org\/10.1111\/1346-8138.16949.","journal-title":"J Dermatol"},{"key":"1103_CR59","doi-asserted-by":"publisher","first-page":"adv6497","DOI":"10.2340\/actadv.v103.6497","volume":"103","author":"S Lofvendahl","year":"2023","unstructured":"Lofvendahl S, Norlin JM, Ericson O, Hanno M, Schmitt-Egenolf M. Prolonged sick leave before and after diagnosis of generalized pustular psoriasis: a Swedish population-based register study. Acta Derm Venereol. 2023;103:adv6497.","journal-title":"Acta Derm Venereol"},{"key":"1103_CR60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jdin.2023.03.012","volume":"12","author":"JE Tarride","year":"2023","unstructured":"Tarride JE, Prajapati VH, Lynde C, Blackhouse G. The burden associated with generalized pustular psoriasis: a Canadian population-based study of inpatient care, emergency departments, and hospital- or community-based outpatient clinics. JAAD Int. 2023;12:90\u20138.","journal-title":"JAAD Int"},{"issue":"2","key":"1103_CR61","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s13555-021-00661-2","volume":"12","author":"B Strober","year":"2022","unstructured":"Strober B, Leman J, Mockenhaupt M, Nakano de Melo J, Nassar A, Prajapati VH, et al. Unmet educational needs and clinical practice gaps in the management of generalized pustular psoriasis: global perspectives from the front line. Dermatol Ther (Heidelb). 2022;12(2):381\u201393.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 1","key":"1103_CR62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-021-00652-1","volume":"23","author":"H Fujita","year":"2022","unstructured":"Fujita H, Gooderham M, Romiti R. Diagnosis of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):31\u20138.","journal-title":"Am J Clin Dermatol"},{"key":"1103_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18851","author":"L Puig","year":"2023","unstructured":"Puig L, Choon SE, Gottlieb AB, Marrakchi S, Prinz JC, Romiti R, et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.18851.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"1103_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.09.080","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Elston CA, Elewski BE, Ferris LK, Gottlieb AB, Lebwohl MG, et al. Generalized pustular psoriasis: a consensus statement from the national psoriasis foundation. J Am Acad Dermatol. 2023. https:\/\/doi.org\/10.1016\/j.jaad.2023.09.080.","journal-title":"J Am Acad Dermatol"},{"key":"1103_CR65","unstructured":"Boehringer Ingelheim. FDA approves the first treatment option for generalized pustular psoriasis flares in adults. (September 01, 2022) Available at: https:\/\/www.boehringer-ingelheim.us\/press-release\/fda-approves-first-treatment-option-generalized-pustular-psoriasis-flares-adults Accessed 14 Nov 2023."},{"key":"1103_CR66","unstructured":"Boehringer Ingelheim. European Commission approves SPEVIGO\u00ae (spesolimab) for generalized pustular psoriasis flares. (December 13, 2022) Available at: https:\/\/www.boehringer-ingelheim.com\/human-health\/skin-diseases\/gpp\/european-commission-approves-spevigo-spesolimab-generalized Accessed 14 Nov 2023."},{"issue":"10","key":"1103_CR67","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMc1811317","volume":"380","author":"H Bachelez","year":"2019","unstructured":"Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981\u20133.","journal-title":"N Engl J Med"},{"issue":"26","key":"1103_CR68","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431\u201340.","journal-title":"N Engl J Med"},{"issue":"17","key":"1103_CR69","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s40265-022-01801-4","volume":"82","author":"HA Blair","year":"2022","unstructured":"Blair HA. Spesolimab: first approval. Drugs. 2022;82(17):1681\u20136.","journal-title":"Drugs"},{"issue":"10412","key":"1103_CR70","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","volume":"402","author":"A Morita","year":"2023","unstructured":"Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541\u201351.","journal-title":"Lancet"},{"key":"1103_CR71","unstructured":"Boehringer Ingelheim. Effisayil\u2122 ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03886246. Accessed 14 Nov 2023."},{"key":"1103_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.178","author":"A Navarini","year":"2023","unstructured":"Navarini A, Bachelez H, Choon S, Burden A, Zheng M, Morita A, et al. 43008 Effisayil ON, an open-label, long-term extension study of spesolimab treatment in patients with generalized pustular psoriasis: interim results for flare treatment. J Am Acad Dermatol. 2023. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.178.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1103_CR73","doi-asserted-by":"publisher","first-page":"584","DOI":"10.5114\/ada.2023.129514","volume":"40","author":"M Jiang","year":"2023","unstructured":"Jiang M, Li Y, Guan X, Li L, Xu W. Rapid response of spesolimab in biologics\u2014failure patient with generalized pustular psoriasis flare. Postepy Dermatol Alergol. 2023;40(4):584\u20136.","journal-title":"Postepy Dermatol Alergol"},{"issue":"1","key":"1103_CR74","doi-asserted-by":"publisher","first-page":"585","DOI":"10.25251\/skin.7.1.4","volume":"7","author":"M Burns","year":"2023","unstructured":"Burns M, Orlowski T, Ho-Pham H, Elston C, Elewski B. New onset generalized pustular psoriasis rapidly improved with IL-36 blockade. SKIN J Cutan Med. 2023;7(1):585\u20138.","journal-title":"SKIN J Cutan Med"},{"issue":"2","key":"1103_CR75","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/jvc2.149","volume":"2","author":"A Fern\u00e1ndez-Galv\u00e1n","year":"2023","unstructured":"Fern\u00e1ndez-Galv\u00e1n A, Daud\u00e9n E, Butron-Bris B, Segu\u00ed-Olmedilla M, Migu\u00e9lez A, Fraga J, et al. First experiences in real clinical practice treating a patient with generalised pustular psoriasis with Spesolimab. JEADV Clin Pract. 2023;2(2):369\u201372.","journal-title":"JEADV Clin Pract"},{"issue":"7","key":"1103_CR76","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/ced\/llad108","volume":"48","author":"D Ran","year":"2023","unstructured":"Ran D, Yang B, Sun L, Wang N, Qu P, Liu J, et al. Rapid and sustained response to spesolimab in five Chinese patients with generalized pustular psoriasis. Clin Exp Dermatol. 2023;48(7):803\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"1103_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.313","author":"JE Gudjonsson","year":"2022","unstructured":"Gudjonsson JE, Randazzo B, Zhou J. 34617 imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: design of a pivotal phase 3 clinical trial and a long-term extension study. J Am Acad Dermatol. 2022. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.313.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1103_CR78","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/bjd\/ljad083","volume":"189","author":"RB Warren","year":"2023","unstructured":"Warren RB, Reich A, Kaszuba A, Placek W, Griffiths CEM, Zhou J, et al. Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. Br J Dermatol. 2023;189(2):161\u20139.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"1103_CR79","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","volume":"23","author":"J Krueger","year":"2022","unstructured":"Krueger J, Puig L, Thaci D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51\u201364.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1103_CR80","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/1744666X.2021.1961580","volume":"17","author":"M Komine","year":"2021","unstructured":"Komine M, Morita A. Generalized pustular psoriasis: current management status and unmet medical needs in Japan. Expert Rev Clin Immunol. 2021;17(9):1015\u201327.","journal-title":"Expert Rev Clin Immunol"},{"key":"1103_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041662","author":"G Avallone","year":"2023","unstructured":"Avallone G, Maronese CA, Murgia G, Carrera CG, Mastorino L, Roccuzzo G, et al. Interleukin-17 vs. interleukin-23 Inhibitors in pustular and erythrodermic psoriasis: a retrospective, multicentre cohort study. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12041662.","journal-title":"J Clin Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01103-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T01:26:28Z","timestamp":1708737988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01103-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1103"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01103-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tina Bhutani is a Principal Investigator for trials sponsored by AbbVie, Castle Biosciences, CorEvitas, Dermavant, Galderma, Mindera, and Pfizer; has received research grant funding from Novartis and Regeneron; and has been an advisor for AbbVie, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Leo, Novartis, Pfizer, Sun Pharma, and UCB. Aaron S. Farberg is an advisory board member for Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Eli Lilly and Company, Galderma, Incyte, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}